Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Express Scripts Holding Co.
Headquarters: St. Louis, MO, United States of America
Website: N/A
Year Founded: 1986
Status: Acquired
BioCentury | Oct 22, 2021
Product Development
Oct. 21 Quick Takes: Express Scripts to prefer biosimilar insulin
Ventyx valuation clears $1B, plus AstraZeneca, bluebird, Pfizer, Merck and more
BioCentury | Sep 28, 2021
Management Tracks
New hires at Brii, Ono and PharmaEssentia to strengthen U.S. leadership
Plus: Ocular, Genprex, SAB and more
BioCentury | Nov 25, 2020
Regulation
With Oxlumo’s approval, Alnylam aims to speed access with new value-based pricing framework
With the approval of Oxlumo to treat primary hyperoxaluria, Alnylam is aiming to accelerate patient access to the ultra-rare disease therapy by building on the performance- and prevalence-based
BioCentury | Aug 8, 2020
Product Development
First oral SMA therapy will be delivered to patients’ homes, well placed for virtual launch
Evrysdi from Genentech, PTC is approved for children and adults, will be priced lower than other SMA drugs
BioCentury | Jan 29, 2020
Product Development
Industry leaders applaud CVS zero co-pay diabetes drug access
CVS is answering the call to decrease the cost burden of diabetes medications on patients
BioCentury | Jan 18, 2020
Product Development
Hard, measurable outcomes drive Express Scripts digital formulary
Express Scripts’ first digital formulary sets evidence bar for reimbursement
BioCentury | Jan 10, 2020
Company News
Management tracks: COO, CMO depart as Solid restructures; plus Abeona, Millendo, Immuneering, Akouos, Kintai, Macrophage, Selexis, Prime
BioCentury | Aug 31, 2019
Product Development
Rethinking first principles
Back to School Part 4: Digital health will call for a new set of first principles for clinical development
BioCentury | May 24, 2019
Company News
AveXis says label makes Zolgensma gene therapy ‘treatment of choice’ for newly diagnosed SMA
Items per page:
1 - 10 of 224